Smartwatch study aims to stop muscle loss in GLP-1 users

NCT ID NCT07226947

Recruiting now Prevention Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether wearing a smartwatch that tracks activity and body composition, along with exercise reminders, can help people on GLP-1 drugs (like Ozempic or Wegovy) maintain muscle and strength. About 100 adults who recently started or plan to start these medications will take part. The goal is to see if this simple approach can safely prevent muscle loss during weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: smartwatch activity and body composition monitor, plus general exercise guidance
What this could lead to: If it works, this could point toward a simple way to help people on GLP-1 drugs keep their muscle while losing weight.
What could go wrong: This is a small, early-stage study with only 100 participants, so results may not apply to everyone. The smartwatch and exercise advice may not be enough to prevent muscle loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BODY COMPOSITION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder muscular atrophy prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BODY COMPOSITION OBESITY

Contacts and locations

Locations

Diabetes Research Center
RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.